

**ASX Announcement**

13 March 2023

**U.S. REGULATORS DECLARE ALL DEPOSITS AT SILICON VALLEY BANK  
WILL BE AVAILABLE MONDAY 13 MARCH 2023 (14 March 2023 AEDT)**

In an ASX announcement released earlier today, Tissue Repair Limited (**'TRP'** or **'the Company'**) (**ASX:TRP**) informed shareholders the Company held cash of US\$2.188million (A\$3.265million) with the Silicon Valley Bank (SVB). The latter was placed into receivership by the Federal Deposit Insurance Corporation (**'FDIC'**) on 10 March 2023 (11 March 2023 AEDT).

Further to the earlier announcement, the U.S. Federal Reserve, Department of Treasury, and the FDIC have since stated on the Department of Treasury's website that they have *"approved actions enabling the FDIC to complete its resolution of Silicon Valley Bank [...] in a manner that fully protects depositors."* The press release continues: *"Depositors will have access to all of their money starting Monday, March 13."* The link to the release is below.

<https://home.treasury.gov/news/press-releases/jy1337>

Based on the U.S. Federal Reserve, Department of Treasury, and the FDIC announcement, the Company expects to be able to access funds held at Silicon Valley Bank on Tuesday, 14 March 2023 AEDT.

The Company's programs continue to progress as previously announced. The Company expects feedback from the FDA on its End of Phase 2 (EOP2) meeting request in Q2CY2023 and expects to launch TR Pro+™ commercially in Q2CY2023.

The Company will continue to provide updates as information becomes available.

For further information in relation to this release please contact CFO, Cameron Jones at [cameron.jones@bio101.com](mailto:cameron.jones@bio101.com) and +61 3 9092 0475.



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566



*This announcement has been approved for release by TRP's board.*

--ENDS--

**About Tissue Repair**

Tissue Repair Limited (ASX:TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering a phase 3 program in chronic wounds for its lead drug candidate TR-987<sup>®</sup>, with a secondary focus on commercialising TR Pro+<sup>TM</sup> a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer-term strategy is to commercialise its propriety Glucoprime<sup>®</sup> API to treat a variety of wounds and skin conditions.



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566